Literature DB >> 2740084

Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings.

C L Shields1, J A Shields, U Karlsson, A M Markoe, L W Brady.   

Abstract

A review of 1019 patients with posterior uveal melanomas who were treated with episcleral plaque radiotherapy showed that 59 (6%) required enucleation of the affected eye. Seventeen of the enucleations were done within 1 year, 30 within 2 years, and 55 within 5 years. The enucleated eyes had been treated with a cobalt-60 plaque in 39 cases, a ruthenium-106 plaque in 13 cases, an iodine-125 plaque in four cases, and an iridium-192 plaque in three cases. The primary reasons for enucleation included tumor regrowth in 30 cases (51%), neovascular glaucoma in 18 (31%), patient request in five (8%), scleral melting in four (7%), painful bullous keratopathy in one (2%), and hemolytic glaucoma in one (2%). The time interval from plaque treatment to eventual enucleation averaged 29 months. Tumor regrowth requiring enucleation was detected clinically an average of 28 months after treatment. In these cases the average radiation dose to the tumor apex was 7700 cGy and to the tumor base 36,000 cGy. Uncontrollable neovascular glaucoma occurred an average of 38 months after plaque radiotherapy and, most commonly, after cobalt-60 plaques were used. Eyes with plaque-induced scleral melting eventually required enucleation after an average of 10 months. In all cases of scleral melting, the tumor was ciliochoroidal.

Entities:  

Mesh:

Year:  1989        PMID: 2740084     DOI: 10.1016/s0161-6420(89)32806-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

Review 1.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

2.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

3.  Scleral necrosis after radiation therapy for uveal melanomas: report of 23 cases.

Authors:  Pietro P Radin; Livia Lumbroso-Le Rouic; Christine Levy-Gabriel; Rémi Dendale; Xavier Sastre; Laurence Desjardins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-03       Impact factor: 3.117

Review 4.  Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review.

Authors:  Luca Tagliaferri; Monica Maria Pagliara; Bruno Fionda; Andrea Scupola; Luigi Azario; Maria Grazia Sammarco; Rosa Autorino; Valentina Lancellotta; Silvia Cammelli; Carmela Grazia Caputo; Rafael Martinez-Monge; György Kovács; Maria Antonietta Gambacorta; Vincenzo Valentini; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2019-02-28

Review 5.  New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Authors:  Krzysztof Bilmin; Kamil J Synoradzki; Anna M Czarnecka; Mateusz J Spałek; Tamara Kujawska; Małgorzata Solnik; Piotr Merks; Mario Damiano Toro; Robert Rejdak; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

6.  Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy.

Authors:  Heng Wang; Ruiheng Zhang; Yining Wang; Rongtian Chen; Yueming Liu; Yang Li; Wenbin Wei
Journal:  BMC Ophthalmol       Date:  2022-04-09       Impact factor: 2.209

7.  Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis.

Authors:  Yuan James Rao; Julia Sein; Shahed Badiyan; Julie K Schwarz; Todd DeWees; Perry Grigsby; Prabakar Kumar Rao
Journal:  J Contemp Brachytherapy       Date:  2017-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.